Antithrombotic Drugs Market 2021 With Competitive Analysis By Top Players 2025
Posted by vamshi krishna on May 28th, 2021
The Antithrombotic Drugs Global Market Report 2020-30 by The Business Research Company describes and explains the global antithrombotic drugs market and covers 2015 to 2020, termed the historic period, and 2020 to 2025, termed the forecast period, along with further forecasts for the period 2025-2030. The report evaluates the market across each region and for the major economies within each region.
The Antithrombotic Drugs Global Market Opportunities And Strategies Report covers antithrombotic drugs market drivers, antithrombotic drugs market trends, antithrombotic drugs market segments, antithrombotic drugs market growth rate, antithrombotic drugs market major players, and antithrombotic drugs market size.
View Complete Report: https://www.thebusinessresearchcompany.com/report/antithrombotic-drugs-market
The antithrombotic drugs market report focuses particularly on identifying the trends, opportunities, and strategies that can lead to success. O&S reports are available off the shelf and can be delivered to clients on the day of purchase.
Antithrombotic Drugs Global Market Opportunities And Strategies Report is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The chapter on the impact of COVID-19 gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market. The chapter also covers markets which have been positively affected by the pandemic.
Request For The Sample Now:
Trends in the market include:
Novel Oral Anti-coagulants (NOACs) To Prevent Thrombosis-
NOACs are gaining wider acceptance and are replacing traditionally used anti-coagulants such as Warfarin and Heparin. Anti-coagulants have long been used in prevention of thrombus formation in patients suffering with cardiovascular diseases. Use of NOACs makes it easier for patients to continue therapy post discharge as opposed to injections of Heparin and Warfarin which need medical assistance for administration. Some of the NOACs include Pradaxa (dabigatran etexilate) from Boehringer Ingelheim, Xarelto (rivaroxaban) from Janssen, and Eliquis (apixaban) from Bristol-Myers Squibb.
Tranexamic Acid To Prevent Postpartum Hemorrhage-
Tranexamic acid is increasingly being used to prevent postpartum hemorrhage (blood loss of over 500 ml or 1,000 ml within 24 hours of childbirth) due to its cheap price and wide availability. Tranexamic acid is an antifibrinolytic drug that helps in reducing bleeding in surgical and trauma patients, including women with postpartum hemorrhage. In April 2017, WOMAN (World Maternal Antifibrinolytic), an international, randomized, double-blind, placebo-controlled trial including over 20,000 women from 193 hospitals in 21 countries, found that using tranexamic acid within three hours of childbirth lowered death from bleeding by 31% and reduced the need for laparotomy (emergency bleeding control surgery) by 36%, as compared to placebo. Tranexamic acids are also used in treating bleeding that can be caused by new antithrombotic drugs such as dagibatran, rivaroxaban, and fondaparinux.
The market is segmented:
1. Anti-Coagulant Drugs
2. Anti-Fibrinolytics Drugs
3. Anti-Platelet Drugs
1. Blood Clot And Thromboembolic Treatment Drugs
2. Hyperlipidemia Treatment
3. Prophylactic Treatment
4. Other Applications
By Drug Class -
By Route Of Administration-
2. Parenteral Route
By Distribution Channel-
1. General Pharmacies
2. Hospital Pharmacies
3. Online Retailers
About The Business Research Company:
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology. It has offices in the UK, the US and India and a network of trained researchers in 20+ countries globally.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293